IBM
IBM sold health care data and analytics assets, part of Big Blue’s Watson Health business, to global investment firm Francisco Partners.
It may be the beginning of the end for Watson Health.
“In the current competitive landscape, IBM would not be considered a significant player in health care,” one expert said. “Selling off the data assets essentially means an end to the Watson Health experiment. However, it may allow IBM as an organization to refocus and develop a new approach to health care.”
Officials at IBM say the sale allows the company to become even more forced on its platform-based hybrid cloud and AI strategy.
Read here to discover what the critics of this deal have to say.
Tags:
